Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Spero Therapeutics (SPRO) Consolidated Net Income (2016 - 2025)

Spero Therapeutics filings provide 10 years of Consolidated Net Income readings, the most recent being $31.5 million for Q4 2025.

  • On a quarterly basis, Consolidated Net Income rose 301.9% to $31.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.6 million, a 113.42% increase, with the full-year FY2025 number at $8.6 million, up 113.42% from a year prior.
  • Consolidated Net Income hit $31.5 million in Q4 2025 for Spero Therapeutics, up from -$7.4 million in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of $52.2 million in Q4 2023 to a low of -$30.1 million in Q1 2022.
  • Median Consolidated Net Income over the past 5 years was -$13.6 million (2023), compared with a mean of -$7.7 million.
  • Biggest five-year swings in Consolidated Net Income: crashed 454.02% in 2024 and later skyrocketed 301.9% in 2025.
  • Spero Therapeutics' Consolidated Net Income stood at -$27.4 million in 2021, then surged by 215.6% to $31.7 million in 2022, then surged by 64.76% to $52.2 million in 2023, then plummeted by 129.89% to -$15.6 million in 2024, then soared by 301.9% to $31.5 million in 2025.
  • The last three reported values for Consolidated Net Income were $31.5 million (Q4 2025), -$7.4 million (Q3 2025), and -$1.7 million (Q2 2025) per Business Quant data.